Global Health Q4 profit jumps 42% as revenue rises, but margins slip as costs weigh on performance

Global Health Limited

reported a strong rise in net profit for the fourth quarter, with earnings growing 41.9% year-on-year (YoY) to ₹143.9 crore, compared with ₹101.4 crore in the corresponding period last year.

Revenue for the quarter increased 24.5% YoY to ₹1,159 crore, up from ₹931.2 crore, reflecting steady growth in operations. However, operating performance showed mixed trends, with EBITDA rising 8.5% YoY to ₹243.7 crore from ₹224.6 crore in the year-ago period.

Despite the growth in profit and revenue, margins contracted during the quarter. EBITDA margin stood at 21%, compared with 24% in the same period last year, indicating pressure on profitability.

The company’s board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The statutory auditors issued an unmodified audit report, confirming that the financial statements present a true and fair view in accordance with applicable accounting standards.

In addition, the board recommended a final dividend of ₹0.50 per equity share of face value ₹2 each for FY26, subject to shareholder approval at the upcoming annual general meeting. If approved, the dividend will be paid within 30 days of the AGM.

The company also announced key senior management changes, including the appointment of Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel, both effective May 14, 2026. Meanwhile, Richa Singh will step down from her role effective May 20, 2026.

Shares of Global Health Limited closed at ₹1,210.30, up ₹14.30 or 1.20% on May 14, 2026.